GSK-3 inhibitor treatment effect on MLL leukemia cell
收藏官方服务：
资源简介：
GSK-3 inhibitor treatment effect on MLL leukemia cell
应用场景：
创建时间：
2010-05-27
相关数据集
Genetic and chemical targeting of the ATPase complex TIP48 and 49 impairs acute myeloid leukemia
The chromatin-associated AAA+ ATPases Tip48 and Tip49 are the core components of various complexes implicated in diverse nuclear events such as DNA repair and gene regulation. Although they are freque
NIAID Data Ecosystem60
Therapeutic potential of spleen tyrosine kinase inhibition for treatment of high-risk precursor B-cell acute lymphoblastic leukemia. Mus musculus
This study revealed pathogenic role of pre-BCR-independent SYK activation in high-risk B-ALL. Intensified and central nervous system (CNS)-directed chemotherapy has significantly improved outcomes for
NIAID Data Ecosystem10
Individual values for figures.
Acute myeloid leukemia (AML) is characterized by several recurrent mutations that affect disease biology and phenotype, response to therapy and risk of subsequent relapse. Though tyrosine kinase inhib
NIAID Data Ecosystem10
Targeting nucleoporin 214 selectively eliminates leukemia stem cells
LSCs from MLL-AF9-driven Nup214fl/fl and Nup214fl/fl,Tie2-Cre AML mice were sorted, followed by further proteomic assay.
NIAID Data Ecosystem20
RNA-seq of K562 cells treated with EPZ-6438 or GSK126. EZH2 inhibitor treatment of CML cell lines (K562, KCL22, AR230-s)
The chronic myeloid leukemia cell lines K562, KCL22, and AR230-s were treated with 2uM of the EZH2 inhibitors EPZ-6438 (Tazemetostat, all cell lines) or GSK126 (K562 only) for 72 hours. RNA-seq was co
NIAID Data Ecosystem10
